The product was distributed in the United States from August 2016 through September 2016.
“Anyone with an existing inventory of the recalled lot should stop use and distribution and quarantine the product immediately,” said the FDA in the release. “Inform healthcare professionals in your organization of this recall. If you have further distributed the recalled product, please notify any accounts or additional locations which may have received the recalled product from you.”
Previous research has classified the formation of particulate matter as one of the major quality concerns in the development of biopharmaceutical products. The possible presence of such particles in the Hospira antibiotic could result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and low-level allergic reactions if injected.
Vancomycin hydrochloride is an antibiotic used to treat multiple conditions including serious infections caused by methicillin-resistant staphylococci. No adverse events involving the Hospira antibiotic have been reported.
More articles on supply chain:
Tom Price open to CMS negotiating drug prices
6 quotes from Dr. Joseph Gulfo — Trump’s potential pick for FDA commissioner
3 ways to improve supplier relationships
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
